This combination treatment leads to G1/S phase arrest in drug-resistant cells, increased tumor growth inhibition (TGI) rate, and complete remission (CR) rate by targeting the PI3K-AKT-mTOR and VHL-HIF pathways to overcome sorafenib resistance (Wang et al., 2024). Here, PIK3CD is linked to neoplasm.